テザカフトル
テザカフトル 物理性質
- 沸点 :
- 610.8±55.0 °C(Predicted)
- 比重(密度) :
- 1.49±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- Store at -20°C , stored under nitrogen
- 溶解性:
- ≥21.8 mg/mL in DMSO; insoluble in EtOH; ≥24.3 mg/mL in H2O
- 外見 :
- solid
- 酸解離定数(Pka):
- 13.99±0.20(Predicted)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露; 気道刺激性 |
3 |
警告 |
|
|
|
注意書き |
P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
P305+P351+P338 |
眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-3441 |
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide |
1152311-62-0 |
250mg |
¥165600 |
2021-03-23 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-3441 |
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide |
1152311-62-0 |
1g |
¥417600 |
2021-03-23 |
購入 |
テザカフトル 化学特性,用途語,生産方法
効能
CFTR調節薬
説明
Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.
使用
Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.
定義
VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface. VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface.
テザカフトル 上流と下流の製品情報
原材料
準備製品
テザカフトル 生産企業
Global( 161)Suppliers
1152311-62-0(テザカフトル)キーワード:
- 1152311-62-0
- VX-661
- VX-661/VX661
- 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide
- Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-
- 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide VX661
- (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-
- CS-956
- VX661/Tezacaftor
- VX 661; VX661;VX-661
- 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
- VX 661;VX661;VX-661; TEZACAFTOR
- Tezacaftor D4Q: What is
Tezacaftor D4 Q: What is the CAS Number of
Tezacaftor D4
- VX-661 USP/EP/BP
- (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-Methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxaMide
- tezacaftor(VX661)
- inhibit,Tezacaftor,Inhibitor,VX-661,Cystic fibrosis transmembrane conductance regulator,Autophagy,VX 661,CFTR
- テザカフトル